 RADNOR, Pa., June 15, 2021 PRNewswire -- NRx Pharmaceuticals Nasdaq: NRXP, a clinical stage pharmaceutical company, today announced positive data from its ZYESAMITM Aviptadil Expanded Access Protocol EAP. 